CRISPR-enhanced LSPR biosensor enables simultaneous ultrasensitive detection of telomerase and fibrin
The study reports a localized surface plasmon resonance biosensor that simultaneously detects telomerase and fibrin by coupling DNA elongation with CRISPR-Cas12a trans-cleavage activity. Under optimized conditions, the platform achieved linear detection across logarithmic concentration ranges with limits of detection of 1.6 × 10⁻¹⁰ IU mL⁻¹ for telomerase and 5 × 10⁻¹⁴ mol L⁻¹ for fibrin. The sensor demonstrated high selectivity and maintained stable signal-to-background ratios over 20 reuse cycles. This dual-target approach offers a potentially more accurate molecular profiling strategy for cancer diagnostics, though clinical validation remains to be established.
The original study
Ultrasensitive, simultaneous detection of two biomarkers with a localized surface plasmon resonance biosensor.
- Authors
- Xu W, Zhang Y, Liu Y, Li L, Shao X, Chen X, et al.
- Journal
- The Analyst
- Type
- Journal Article
- PMID
- 42459060
Original abstract
A localized surface plasmon resonance (LSPR) biosensor was developed for the simultaneous detection of two components, namely telomerase and fibrin, based on the impact of single-stranded DNA (ssDNA) length on LSPR variations. First, short-stranded ssDNA, consisting of (TTAGGG)2 bases, is immobilized onto the surface of an AuNP chip. Regarding the detection of telomerase, the latter is capable of catalyzing the elongation process by adding a repeating DNA sequence (TTAGGG)n. The elongation of the ssDNA length prompts an increase of the LSPR signal. Subsequently, in the presence of fibrin, the CREKA-fibrin-antibody sandwich structure positions two DNA probes in close proximity, enabling the formation of a CRISPR-Cas12a targetable double-stranded DNA (dsDNA). This event triggers the trans-cleavage activity of Cas12a, which can cleave the elongated ssDNA on the chip surface. As a result of this process, a decrease in the LSPR signal is observed. Under optimal conditions, the LSPR signals corresponding to both telomerase and fibrin exhibited a linear relationship with the logarithm of the telomerase and fibrin concentrations. The detection limits were 1.6 × 10-10 IU mL-1 for telomerase and 5 × 10-14 mol L-1 for fibrin, respectively. The proposed methodology demonstrated high sensitivity, selectivity, and reusability, with minimal change in the signal-to-background (S/B) ratio observed over 20 cycles using the same chip. This approach is likely to yield a more accurate cancer diagnosis via the detection of double biomarkers.